We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Silicon Microparticles Boost Effectives of Potential Breast Cancer Vaccines

By LabMedica International staff writers
Posted on 19 May 2015
Print article
Image: The porous silicon microparticles are about one micrometer in diameter. The hollow channels within each microparticle can be loaded with antigens—such as HER2—that can help train the immune system to recognize and destroy cancer cells overexpressing HER2 (Photo courtesy of Dr. Haifa Shen\'s laboratory, Houston Methodist Research Institute).
Image: The porous silicon microparticles are about one micrometer in diameter. The hollow channels within each microparticle can be loaded with antigens—such as HER2—that can help train the immune system to recognize and destroy cancer cells overexpressing HER2 (Photo courtesy of Dr. Haifa Shen\'s laboratory, Houston Methodist Research Institute).
Microparticles constructed from porous silicon were found to increase the effectiveness of potential anti-breast-cancer vaccines by stimulating a type I interferon response even when not carrying any specific antigen.

Investigators at Houston Methodist Research Institute (Texas, USA) were interested in improving the performance of vaccines targeting the breast cancer HER2 oncoprotein. These vaccines have mostly not been very potent because of inefficient vaccine delivery, a poor immune response at the site of the tumor, and other factors.

In a study published in the April 30, 2015, online edition of the journal Cell Reports, the authors described the use of porous silicon microparticles (PSM) as delivery vehicles for anti-HER2 vaccines. They reported that a PSM-based cancer vaccine displayed greatly enhanced cross-presentation and activated type I interferon (IFN-I) response in dendritic cells. PSM-loaded antigen exhibited prolonged early endosome localization and enhanced cross-presentation through both proteasome- and lysosome-dependent pathways. Dendritic cells primed with PSM-loaded HER2 antigen produced robust CD8 T-cell-dependent anti-tumor immunity in mice bearing HER2+ mammary gland tumors.

"We have shown for the first time that a microparticle can serve as a carrier for sustained release and processing of tumor antigens," said senior author Dr. Haifa Shen, professor of nanomedicine at Houston Methodist Research Institute. "But just as importantly, we learned the microparticles themselves appear to be enough to stimulate a type I interferon response, and were even transferred from one antigen-presenting cell to another to maintain a long-lasting antigen-releasing effect. PSMs persistently challenge the antigen-presenting cells to activate the T-cells, and the PSMs modify the tumor microenvironment so that the cytotoxic T-cells maintain their activity."

"We could completely inhibit tumor growth after just one dose of the cancer vaccine in the animal model," said Dr. Shen. "This is the most amazing result we have ever seen in a tumor treatment study."

Related Links:

Houston Methodist Research Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.